INVESTOR ALERT: Levi & Korsinsky is Investigating Alec Stock After its Phase 3 INFRONT-3 Clinical Trial Misses Co-Primary Endpoint

Core Viewpoint - Alector, Inc. has faced disappointment following the announcement of mixed topline results from its Phase 3 INFRONT-3 trial, which evaluated the efficacy of latozinemab in treating frontotemporal dementia due to a gene mutation [2][4][5] Group 1: Trial Results - The Phase 3 INFRONT-3 trial aimed to evaluate the efficacy of latozinemab in slowing disease progression in patients with frontotemporal dementia due to a progranulin gene mutation, enrolling 119 patients with a mean age of 62.1 years [3] - The trial had two co-primary endpoints: biomarker response, which was met, and clinical response, which was not met, as the trial failed to achieve its efficacy-based co-primary endpoint of slowing FTD-GRN progression [4] Group 2: Investor Reaction - Following the release of the mixed topline results, analysts expressed disappointment and subsequently downgraded Alector's stock [5]